Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 13.10.2025 3 BJU Int 1 BMC Cancer 1 BMJ Oncol 1 Br J Cancer 2 Cancer 9 Eur Urol 1 Hum Pathol 2 Int J Urol 2 J Nucl Med 3 J Urol 1 Mod Pathol 1 PLoS One 7 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. SIGHINOLFI MC, Pallotta G, Assumma S, Panio E, et al
   A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease.
   BJU Int. 2025 Oct 10. doi: 10.1111/bju.70019.
   PubMed         Abstract available
   
   
2. MARQUIS A, Schwartz MJ, Armache A, Solosky K, et al
   Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights.
   BJU Int. 2025 Oct 9. doi: 10.1111/bju.70014.
   PubMed         Abstract available
   
   
3. GILL S, Chen R, Lamb BW, Moore CM, et al
   Interventions for patients with prostate cancer on active surveillance: a narrative review.
   BJU Int. 2025 Oct 6. doi: 10.1111/bju.70005.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. GHOLIZADE M, Yazdani E, Hosseini-Baharanchi FS, Nikoofar A, et al
   Variations in radiomic features of the femoral head and neck during helical tomotherapy in prostate and rectal cancer patients.
   BMC Cancer. 2025;25:1509.
   PubMed         Abstract available
   
   

   
   BMJ Oncol

5. STEWART KT, Choudhury A
   Understanding prostate cancer care: recent progress and future direction.
   BMJ Oncol. 2025;4:e000985.
   PubMed        
   
   

   
   Br J Cancer

6. NIKHIL K, Haymour HS, Kamra M, Shah K, et al
   Correction: Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
   Br J Cancer. 2025 Oct 9. doi: 10.1038/s41416-025-03212.
   PubMed        
   
   

   
   Cancer

7. TSUNG I, Reichert ZR, Ramalingam SS
   Reply to "From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer".
   Cancer. 2025;131:e70119.
   PubMed        
   
   
8. ROVIELLO G, Catalano M, Antonuzzo L
   From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
   Cancer. 2025;131:e70117.
   PubMed        
   
   

   
   Eur Urol

9. WANG Z, Li X, Zhao X, Yang Y, et al
   Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In press. https:/
   Eur Urol. 2025 Oct 9:S0302-2838(25)04728-1. doi: 10.1016/j.eururo.2025.
   PubMed        
   
   
10. IORI F, Ali E, Iotti C
    Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In pre
    Eur Urol. 2025 Oct 9:S0302-2838(25)04726-8. doi: 10.1016/j.eururo.2025.09.4167.
    PubMed        
    
    
11. MENG X, Hua Y, Song R
    Re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol 20
    Eur Urol. 2025 Oct 9:S0302-2838(25)04727-X. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
12. ENGLMAN C, Giganti F, Moore CM
    Reply to Francesco Montorsi, Paolo Zauirto, and Giorgio Gandaglia's Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results
    Eur Urol. 2025 Oct 7:S0302-2838(25)04703-7. doi: 10.1016/j.eururo.2025.09.4153.
    PubMed        
    
    
13. KHALIL N, Maiolino G, Barret E
    Re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives. Eur Urol 2025;88:123-5.
    Eur Urol. 2025 Oct 6:S0302-2838(25)04709-8. doi: 10.1016/j.eururo.2025.09.4159.
    PubMed        
    
    
14. HOLMBERG L, Adami HO, Bill-Axelson A
    Reply to Yafei Wang, Qianting Lu, and Xin Zhao's Letter to the Editor re: Lars Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early P
    Eur Urol. 2025 Oct 6:S0302-2838(25)04701-3. doi: 10.1016/j.eururo.2025.09.4151.
    PubMed        
    
    
15. VICKERS AJ, Touijer K
    Re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 2025;87:619-21.
    Eur Urol. 2025 Oct 6:S0302-2838(25)04694-9. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
16. LIN PH, Burwell AD, Freedland SJ
    Reply to Nastasiia Artamonova and Isabel Heidegger's Letter to the Editor re: Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studie
    Eur Urol. 2025 Oct 4:S0302-2838(25)04706-2. doi: 10.1016/j.eururo.2025.09.4156.
    PubMed        
    
    
17. GRAEFEN M, Falkenbach F, Maurer T, Budaus L, et al
    Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial.
    Eur Urol. 2025 Oct 3:S0302-2838(25)04687-1. doi: 10.1016/j.eururo.2025.09.4144.
    PubMed         Abstract available
    
    

    
    Hum Pathol

18. LIN R, Li H, Baraban E, Lotan T, et al
    Atypical intraductal proliferation (AIP) of the prostate: Findings in repeat biopsy or radical prostatectomy in patients who met pathologic criteria for active surveillance.
    Hum Pathol. 2025;160:105841.
    PubMed         Abstract available
    
    

    
    Int J Urol

19. YASUDA Y, Wang Z, Yoshida S, Chen W, et al
    Indirect Comparison of PROpel and TALAPRO-2 Trials Using the Shiny Method: A Comparative Analysis in Metastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Aug 12. doi: 10.1111/iju.70194.
    PubMed        
    
    
20. ESCANDE R, Jaouen T, Gonindard-Melodelima C, Crouzet S, et al
    External Validation on a Japanese Cohort of a Computer-Aided Diagnosis System Aimed at Characterizing ISUP >/= 2 Prostate Cancers at Multiparametric MRI.
    Int J Urol. 2025;32:1440-1448.
    PubMed         Abstract available
    
    

    
    J Nucl Med

21. CHEN DC, Buteau JP, Papa N, Akhurst T, et al
    Prognostic Value of Initial Imaging and PSA Change with [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
    J Nucl Med. 2025 Oct 9:jnumed.125.270804. doi: 10.2967/jnumed.125.270804.
    PubMed         Abstract available
    
    
22. MADSEN C, Zacho HD, Fuglo D, Nielsen K, et al
    (18)F-PSMA PET/CT Versus (18)F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study.
    J Nucl Med. 2025 Oct 9:jnumed.125.270822. doi: 10.2967/jnumed.125.270822.
    PubMed         Abstract available
    
    

    
    J Urol

23. KUMAR R, Lajkosz K, Hiemstra J, Finelli A, et al
    Characterizing the Impact of Novel Patient-Centered Pathology Reports on Men Undergoing Prostate Biopsy: The Patient-Centered Pathology Report Randomized Controlled Trial.
    J Urol. 2025;214:509-520.
    PubMed         Abstract available
    
    
24. EIGL BJ, Elangovan A, Ghosh S, Kim JO, et al
    A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.
    J Urol. 2025;214:496-508.
    PubMed         Abstract available
    
    
25. KOKOROWSKI P, Friedrich NA, Luu M, Shiang A, et al
    Patient Participation in Consultations for Clinically Localized Prostate Cancer.
    J Urol. 2025 Oct 10:101097JU0000000000004814. doi: 10.1097/JU.0000000000004814.
    PubMed         Abstract available
    
    

    
    Mod Pathol

26. JENNIFER NGUYEN NN, Liu K, Lajkosz K, Bernardino R, et al
    Corrigendum to "Magnetic Resonance Imaging (MRI)-Adapted Prostate Cancer Risk Tool Incorporating Cribriform and Intraductal Carcinoma" (Modern Pathology 2025 Dec;38(12):100852).
    Mod Pathol. 2025;38:100893.
    PubMed        
    
    

    
    PLoS One

27. MURTOLA TJ, Skantsi KM, Siltari A, Talala K, et al
    SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients.
    PLoS One. 2025;20:e0329438.
    PubMed         Abstract available
    
    

    
    Prostate

28. WHYNE EZ, Choi SH, Unni N, Kanjwal S, et al
    Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core.
    Prostate. 2025 Oct 8. doi: 10.1002/pros.70074.
    PubMed         Abstract available
    
    
29. LIU Y, Wang H, Wang Z, Wang J, et al
    The Infiltration of IL-18-Related Immune Cells and Their Bidirectional Regulatory Roles in the Pathogenesis of Prostate Cancer.
    Prostate. 2025 Oct 7. doi: 10.1002/pros.70077.
    PubMed         Abstract available
    
    
30. MULCRONE J, Noakes J, Braunagel T, Hankins-Chace K, et al
    Lessons Learned From a Mindfulness Intervention Study in Men With Newly Diagnosed Prostate Cancer.
    Prostate. 2025 Oct 7. doi: 10.1002/pros.70076.
    PubMed        
    
    
31. MADENDERE S, Esen B, Karaarslan UC, Muduroglu M, et al
    Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology.
    Prostate. 2025 Oct 6. doi: 10.1002/pros.70073.
    PubMed         Abstract available
    
    
32. TILLU N, Schussel K, P Kolanukuduru K, Choudhary M, et al
    Diagnostic Utility of 18F-DCFPyL PSMA PET/CT-Ultrasound Fusion Biopsies Across the Prostate Cancer Spectrum.
    Prostate. 2025 Oct 6. doi: 10.1002/pros.70068.
    PubMed         Abstract available
    
    
33. NAKAI Y, Onishi K, Asakawa I, Miyake M, et al
    Evaluating Local Doses for Prostate Cancer Treatment Using Low-Dose-Rate Brachytherapy Considering Oncological Control and Toxicity.
    Prostate. 2025 Oct 6. doi: 10.1002/pros.70039.
    PubMed         Abstract available
    
    
34. ROSALES RDR, Venkatesh A, Kanumuambidi JP, Ishiyama Y, et al
    Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer.
    Prostate. 2025 Oct 5. doi: 10.1002/pros.70070.
    PubMed         Abstract available
    
    

    
    Urology

35. ORCUTT DJ, Chisholm L, Winkler E, Kaufman MR, et al
    Patient-Centered Priorities in Prostate Cancer Survivorship Care.
    Urology. 2025 Oct 2:S0090-4295(25)00940-9. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.